Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals Inc. reported that new research on PEDMARK® (sodium thiosulfate injection) will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. Four independently led studies examine use of PEDMARK across pediatric, adolescent, young adult and adult patients receiving cisplatin-based chemotherapy.
Key data include a Japanese Phase 2/3 trial in 27 pediatric and adolescent patients where hearing loss rates of 16–24% with PEDMARK were lower than historically reported 56–63% with cisplatin alone, and real‑world series in young adults and adults with head and neck cancer suggesting feasible integration of PEDMARK several hours after cisplatin without compromising antitumor activity and with preservation of clinically significant hearing. The company also reiterates that PEDMARK is the first FDA‑approved therapy to reduce cisplatin‑related ototoxicity in pediatric patients with localized, non‑metastatic solid tumors.
Fennec Pharmaceuticals Inc. disclosed that its board’s Compensation Committee approved inducement stock option grants for three new non-executive employees. The awards cover an aggregate of 50,000 common shares under the 2026 Equity Inducement Plan as inducement grants pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $9.75 per share, a ten-year term, and vest over three years, with one-third vesting on the first anniversary of the May 18, 2026 grant date and the remainder vesting monthly over the following 24 months, subject to continued employment. A press release with further details was furnished as an exhibit.
FENNEC PHARMACEUTICALS INC. Schedule 13G/A (Amendment No. 3) reports that Solas Capital Management, LLC and Frederick Tucker Golden each hold 2,482,198 common shares, representing 7.2% of the class based on 34,475,178 shares outstanding as of March 20, 2026.
The filing states the reported holdings reflect shared voting and dispositive power of 2,482,198 shares and confirms the investment adviser/portfolio manager relationship; the Funds disclaim beneficial ownership pursuant to Rule 13d-4.
Fennec Pharmaceuticals Inc. reported strong quarterly growth as PEDMARK product sales, net, rose to $15.1 million for the three months ended March 31, 2026, up from $8.8 million a year earlier. Higher revenue helped the company swing from a net loss of $1.2 million in 2025 to net income of $0.2 million and positive operating cash flow of $2.4 million. Cash and cash equivalents increased to $40.2 million, with working capital of $57.3 million, and management believes this is sufficient to fund operations for at least twelve months. Fennec also highlighted its ex‑U.S. PEDMARQSI® license with Norgine, which included an upfront payment of about $43 million and potential milestones up to roughly $230 million, and a settlement with Cipla that delays U.S. generic sodium thiosulfate entry until September 1, 2033 under agreed terms.
FENNEC PHARMACEUTICALS INC. filing amends a Schedule 13G/A to report beneficial ownership stakes by Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon. The filing states ownership percentages of 8.8% (Rosalind Advisors), 8.4% (Rosalind Master Fund), and 8.6% each for Steven Salamon and Gilad Aharon, based on 34,712,756 shares outstanding as of April 13, 2026.
The statement breaks down voting and dispositive powers: the Advisor and the Master Fund hold shared voting and disposition authority over 2,908,201 shares (reported in Item 4), while Mr. Salamon and Mr. Aharon individually report 66,666 shares of sole voting and dispositive power. The filing includes disclaimers from the Advisor and Mr. Salamon regarding beneficial ownership.
FENNEC PHARMACEUTICALS INC. director Chris A. Rallis reported an option exercise combined with a related share sale. He exercised stock options covering 14,344 Common Shares at $2.44 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025. To cover tax obligations from this exercise, 8,346 Common Shares were sold at an average price of $7.04 per share. After these transactions, Rallis directly holds 63,077 Common Shares, reflecting a net increase in his equity position from the option exercise.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported an options-related share transaction in FENC. He exercised stock options to acquire 15,598 common shares at $2.45 per share and also received 2,778 previously restricted shares. On the same day, he sold 10,781 common shares in an open-market sale at $6.47 per share to satisfy tax obligations related to the option exercise, all under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. Following these transactions, Raykov directly holds 121,451 common shares.
FENC insider sale notice: A Form 144 was filed reporting a proposed sale of 10,781 shares of Common Stock via a stock option exercise on 05/01/2026. The filing lists prior cash sales by Rostislav Raykov of 10,946, 10,079 and 10,349 shares on 04/01/2026, 03/02/2026 and 02/02/2026 respectively, with the reported cash amounts shown in the record.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans acquired 168 Common Shares through an exercise or conversion of a derivative security at a stated price of $0.00 per share. A footnote explains these represent shares released from restriction from shares awarded on 3/28/2025. Following this transaction, Evans directly holds 20,847 Common Shares.